However, in countries such as Japan, where the HP infection rate is high, prediction of GC risk based solely on the presence or absence of HP infection does not offer sufficient specificity. Elucidation of groups at high risk based on the natural history of GC is clearly necessary. The identification of useful markers of GC risk is thus hoped for. Evaluating HP-related chronic gastritis and determining which subjects are at high risk for developing GC is very important, and would likely increase the efficacy of GC screening by endoscopic or other examinations (Enomoto et al., 2010a; Mukoubayashi et al., 2007; Ohata et al., 2005), and strategic approaches to metachronous multiple GC after endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) performed as minimally invasive treatment for early GC (Gotoda, 2007; Kakushima & Fujishiro, 2008; Nakajima et al., 2006). In addition, in terms of GC prevention, it has become clear that HP-related chronic gastritis cannot be ignored as an origin of carcinogenesis.
Here, we discuss the significance of serum pepsinogen (PG) as a marker of GC risk and GC high-risk groups based on HP-related chronic gastritis. We also discuss the prevention for individuals with HP-related chronic gastritis.
2. GC risk diagnosis based on the natural history of HP-related chronic gastritis
Novel risk markers to identify GC high-risk groups based on a detailed natural history of HP-related chronic gastritis have long been awaited. In this section, we discuss the emerging significance of serum PG as a GC risk marker for more precise identification of GC high-risk groups.
2.1. Serum PG test
HP-related chronic gastritis usually starts in the antrum and expands proximally towards the body of the stomach (Kimura, 1972; Tatsuta et al., 1973). As several studies dealing with endoscopic biopsies or chromoendoscopic testing have found that progression of chronic atrophic gastritis (CAG) increases the risk of cancer (Meister et al., 1979; Sipponen et al., 1985; Siurala et al., 1966; Tatsuta et al., 1993; Testoni et al., 1987), accurate and reliable evaluation of the extent of CAG is considered important for identifying individuals at high risk of cancer. However, accurately diagnosing the extent of CAG based on a few biopsy samples is difficult, because CAG together with intestinal metaplasia is a multifocal process. Furthermore, histological diagnosis of gastric atrophy depends on subjective judgment without a gold standard (Guarner et al., 1999; Plummer et al., 1997). A test for CAG progression that is more convenient, free of discomfort or risk, economical and based on objective parameters is needed.
PG is the inactive precursor of pepsin, a digestive enzyme specifically produced in the stomach. Immunologically, two isozymes exist (Kageyama, 2003). PGI is produced by chief cells and mucus neck cells of the gastric fundic glands. In contrast, PGII is produced not only by chief cells and mucus neck cells, but also in cardiac glands, pyloric glands, and Brunner’s glands, with localization of producing cells in a wide range from the stomach to the duodenum. The majority of PG produced (about 99%) is secreted in the stomach lumen and functions as a digestive enzyme. However, a small amount of PG (about 1%) is also present in blood and can be evaluated by measuring serum PG levels. Serum PG levels are generally agreed to reflect the morphological and functional status of the stomach mucosa (Hirschowitz, 1957; Samloff et al., 1982).
In an endoscopic study with Congo red staining, we have shown a strong correlation between an increase in glandular boundary, associated with diagnosed progression of gastric mucosal atrophy, and stepwise reductions in serum PGI levels and the PGI/PGII ratio (Fig. 1) (Miki et al., 1987). In other words, by measuring serum PGI and the PGI/II ratio, the progression of CAG, which is involved in GC carcinogenesis, can be objectively evaluated (Ichinose et al., 2001). In addition, during HP infection, serum PGI and PGII increase, and the PG I/II ratio decreases. These findings are improved after eradication treatment (Furuta et al., 1997) and are useful as gastric mucosal inflammatory markers.
Several criteria are used in the serum PG test. As criteria for GC screening, the combination of PGI ≤70 ng/ml and PGI/II ratio ≤3.0, as a reference value by Miki et al., is widely accepted (PG index 1+) (Ichinose et al., 2001; Watanabe et al., 1997). Values lower than this
reference value are considered PG-test positive. In addition to this reference value, to identify more severe CAG progression, criteria of PGI ≤50 ng/ml and PGI/II ratio ≤3.0 (PG index 2+), and PGI ≤30 ng/ml and PGI/II ratio ≤2.0 (PG index 3+) are also used. Since 1992, when PG assay kits became commercially available, a number of screening services provided by workplaces or community health services have adopted this serum test as a filter test (Hattori et al., 1995; Kitahara et al., 1999; Kodoi et al., 1995; Miki et al., 1993; Miki et al., 2003; Ohata et al, 2005; Yoshihara et al., 1997). However, the long-term prognosis of subjects with extensive CAG identified by PG filter test is not fully known.
2.2. Detection accuracy of GC using the serum PG test
We conducted a large-scale cohort study spanning more than 10 years in Wakayama Prefecture, Japan, and identified groups at high risk for GC (Ohata et al., 2004; Yanaoka et al., 2008a; Yanaoka et al., 2008b). Based on the results, accuracy of each criteria of the serum PG test for GC that occurred during the observation period was evaluated (Yanaoka et al, 2008a). Accuracy of the criteria is shown in Table 1. For the most favorable criteria (PG index 1+), sensitivity was 58.7%, specificity was 73.4%, and positive predictive value was 2.6%. Compared to a meta-analysis of PG test sensitivity (Dinis-Ribeiro et al., 2004), these results were poor, particularly in terms of sensitivity.
As a reason for these poor results, the presence of GC easy to detect by barium X-ray, and GC easy to detect by the serum PG test, was cited (Ohata et al, 2005). In the above-mentioned meta-analysis, many of the previously reported cases that were reviewed were from studies in populations in which GC screening by conventional barium X-ray had been conducted over a period of many years. In other words, that study reviewed results for GC
detection just after introduction of the serum PG test, over a short period, and targeting a population in whom GC was difficult to detect by barium X-ray, i.e., those in whom GC was easy to detect by the serum PG test. On the other hand, GC cases just after introduction of the serum PG test were excluded from our study, and observation was over a long period of 10 years. Accordingly, results for the detection of GC occurring during the observation period were more rigorously evaluated, and thus more correctly reflective of the accuracy for detecting GC by the serum PG test. Based on the above results, using the serum PG test alone for GC screening has limitations. A more elaborate system must therefore be developed, including for GC screening in PG test-negative cases.
2.3. GC risk in a serum PG test-positive group
Previous studies have examined the accuracy of the serum PG test as a filter test for endoscopy. Recently, as part of an investigation into the natural history of GC occurrence, we evaluated GC risk in populations identified by each criteria for the serum PG test (Yanaoka et al, 2008a). In a population of middle-aged healthy men, in an atrophy-negative group, the annual incidence of GC was 0.07%. In contrast, annual incidence was 0.28% in the PG index 1+ group, 0.32% in the PG index 2+ group, and 0.42% in the PG index 3 +group, showing significant stepwise increases in GC incidence with CAG progression (Fig. 2) Based on these results, PG test-positive groups, as assumed, are high-risk groups for GC. In other words, an individual who is serum PG test-positive, even if GC is not currently detectable, still has a high possibility of developing GC in the future. Careful monitoring with detailed testing is clearly indicated in such subjects. This again demonstrates the usefulness of the PG test as a marker of high risk for GC.
2.4. Natural history of HP-related chronic gastritis and GC risk
In addition to the serum PG test, the natural history of HP-related chronic gastritis and associations with GC risk have been examined by evaluating HP infection, as the major cause of onset and progression of chronic gastritis in Japan (Ohata et al, 2004; Yanaoka et al, 2008b). HP infection is diagnosed using anti-HP antibody titers, which, like the serum PG test, is a blood test that is easy to perform. The stages of HP-related chronic gastritis, from
the onset of HP infection to development of atrophic gastritis, can be classified based on a combination of both serum blood tests: Group A [HP(-), PG(-)], Group B [HP(+), PG(-)], Group C [HP(+), PG(+)], and Group D [HP(-), PG(+)]. Group A comprised HP non-infected healthy subjects. Group B showed established HP infection, but without extensive CAG. Group C had extensive CAG. Group D had severe intestinal metaplasia due to progression of CAG, but HP had been spontaneously eliminated, representing so-called metaplastic gastritis.
The natural history of HP-related chronic gastritis from the onset of HP infection can be shown to progress from each stage: A→B→C→D. Based on a follow-up study, the annual incidence of GC for each group using this stage classification was: 0% for Group A (no occurrence of GC during 10 years in this group); 0.11% for Group B (GC in 1 per 1000 patients per year); 0.24% for Group C (GC in 1 per 400 patients per year); and 1.31% for Group D (GC in about 1 per 80 patients per year). Based on these data, with progression in stage of HP-related chronic gastritis, a stepwise increase is seen for GC incidence (Fig. 3). Similar results were reported by Watabe et al. (Watabe et al., 2005). During the 10-year follow-up study, all patients who developed GC were HP infection-positive. These results showed that in Japan, almost all cases of GC are associated with HP-related chronic gastritis. Theoretically, based on this fact, not only a GC high-risk group, but also a GC low-risk group (group A), can be identified. This is expected to contribute greatly to suitable and more intensive GC screening.
2.5. Points in the diagnosis of GC risk using the serum PG test
The serum PG test is clearly a highly useful test for a GC risk marker. However, the occurrence of GC (particularly diffuse-type GC) in PG test-negative groups (group B in the stage classification for HP-related chronic gastritis) cannot be ignored. In our study, even when using the PG test criteria considered as the most balanced in terms of test accuracy (PG index 1+), the fact remains that about 40% of GC cases are PG test-negative. When diagnosing GC risk using the serum PG test, this fact must be carefully considered.
We therefore carefully investigated GC occurrence in a PG test-negative group. Specifically, to evaluate GC incidence, we subdivided the PG test-negative group into 3 groups: α group (serum PGI ≤70 ng/ml and PGI/II >3); β group (serum PGI >70 ng/ml and PGI/II >3), and γ group (serum PGI >70 ng/ml and PGI/II ≤3). The results identified a new group at high risk of GC, with GC incidence in the γ group (high serum PGII levels and severe inflammation of the gastric mucosa) reaching 0.2%, predominantly involving undifferentiated GC (Yanaoka et al, 2008a). This rate in the γ group, although not necessarily high among the PG test-negative group, still indicates a subgroup that deserves particular attention. In addition, a group with high HP antibody titer (a marker that, like serum PGII level, reflects severity of inflammation) showed higher incidence of GC compared to a low-titer group (Yanaoka et al, 2008b).
Among PG test-negative groups, in group A of the stage classification for HP-related chronic gastritis (PG test-negative and HP-negative), we observed no occurrence of GC over a 10-year follow-up period. However, some cautionary points must be considered in a confirmatory diagnosis of Group A status. First, with HP antibody assay kits showing low sensitivity, antibody titers may be negative despite prior HP infection. Second, in HP-negative cases after eradication therapy, it should be kept in mind that “although HP is negative, the risk of GC is not zero.” Third, risk assessment by the serum PG test cannot be applied in subjects with post-gastrectomy,with renal insufficiency, using proton pump inhibitors, or showing an acute gastric mucosal lesion (AGML). In addition, we have reported that in subjects with a PGI/II ratio ≤3.0, serum PGI ≤30 ng/ml, or serum PGII >30 ng/ml, the risk of GC is significantly higher (Yanaoka et al, 2008b). Based on these data, even among group A patients, if the PGI/II ratio is ≤3.0 or serum PGI is ≤30 ng/ml, endoscopy should be performed once to evaluate the possible presence of CAG.
3. Prevention of GC based on the natural history of HP-related chronic gastritis
The evaluation of HP-related chronic gastritis is especially important in the analysis of GC prevention. However, previous studies have not assessed the extent of coexisting CAG or have assessed it only with endoscopic findings and/or histopathology on endoscopic biopsy. In this section, we discuss the strategy of GC prevention according to the evaluation of HP-related chronic gastritis based on the serum PG test.
3.1. Prevention of GC by HP eradication
Many previous studies have been conducted on the inhibition of GC by eradication therapy for HP, a major factor in gastric carcinogenesis. HP eradication therapy has recently been shown to prevent metachronous cancer after endoscopic resection of early GC (Fukase et al., 2008). However, in several reports to date, the effects on prevention of GC have not been as clear-cut as the effects of HP eradication on prevention of peptic ulcers. The studies that found inhibitory effects on gastric carcinogenesis were often non-randomized studies with a short observation period of 5 years (Fuccio et al., 2007). Moreover, results have been mixed. For example, in studies of GC occurrence after HP eradication in groups with or without precancerous lesions (CAG or intestinal metaplasia), significant inhibition of GC in the without-precancerous-lesion group was reported (Take et al., 2007; Wong et al., 2004). On the other hand, absence of inhibition of GC, regardless of the presence or absence of precancerous lesions, has also been reported (You et al., 2006). In contrast, in an animal study using HP-infected Mongolian gerbils, inhibition of gastric carcinogenesis by HP eradication was clearly demonstrated (Tatematsu et al., 2007).
These study results suggest several points. First, inhibition of gastric carcinogenesis by HP eradication is not complete, and even after eradication, more than a few GC cases have been observed. Second, the earlier during infection that eradication therapy is started, the greater the inhibitory effect on GC. Third, after a duration has elapsed, irreversible changes due to HP infection develop, representing a “point of no return”. This suggests an attenuated eradication effect. Fourth, HP infection promotes the proliferation and growth of cancer cells that have already developed (promoter effect). During long-term observation, clear-cut inhibition of gastric carcinogenesis by HP eradication is not seen, but eradication groups with shorter observation periods may display apparent inhibition of GC, with slower growth rates, and without growth of cancer that can be clinically diagnosed. Fifth, besides promoter effects on GC, HP infection, as previously described in detail, is also involved in gastric carcinogenesis mediated through the development and progression of CAG and intestinal metaplasia. To achieve a reduction in GC risk by eradication, in addition to HP elimination, improvement of CAG and intestinal metaplasia is necessary.
Based on these points, when evaluating the prevention of GC by HP eradication, evaluation of the equivalence of GC risk in the eradication group and non-eradication group (control) is necessary. With regard to this point, in almost all previous studies, either evaluation of CAG progression has been lacking, or even if evaluated, endoscopic or histopathologic findings, with strong subjective elements, were used. We therefore conducted a 10-year follow-up study in middle-aged healthy adults in whom progression of atrophic gastritis was monitored by serum PG (Yanaoka et al., 2009). In that study, although non-randomized, both the HP eradication and control groups showed equivalence with regard to CAG progression (an important risk factor), in addition to major risk factors for GC such as age, gender, and smoking. In this study, no significant inhibition of GC was observed even with HP eradication.
However, with assessment by the PG test, evaluation in the PG test-positive (extensive CAG) and PG test-negative (non-extensive CAG) groups showed that HP eradication in the PG test-positive group did not prevent GC, whereas HP eradication in the PG test-negative group only achieved significant inhibition of GC (Fig. 4). These results confirm the
previously mentioned results that assumed that no significant prevention of GC by HP eradication was achieved due to advanced CAG. This strongly suggests that in the majority of PG test-positive subjects, the stomach is past the “point of no return.” The significance of HP eradication thus lies in achieving: 1) a decrease in GC proliferation and growth rates by inhibiting the GC-promoting effects of HP; 2) inhibition of carcinogenesis by halting progression of CAG; and 3) inhibition of inflammation-based gastric carcinogenesis (particularly diffuse-type GC) by healing chronic active gastritis. In fact, our study also showed that diffuse-type GC can be significantly inhibited by HP eradication.
3.2. Chemoprevention of GC by NSAIDs
Although prevention of GC by HP eradication can be expected, from a more realistic perspective, the effectiveness may be somewhat limited. In particular, among patients with advanced CAG, the chemopreventive effects of HP eradication therapy alone are unlikely to be sufficient. In populations where inhibition of gastric carcinogenesis cannot be achieved by HP eradication therapy alone, chemoprevention with the use of non-steroidal anti-inflammatory drugs (NSAIDs) is promising as a treatment strategy. Cyclooxygenase (COX) is a rate-limiting enzyme of prostaglandin synthesis in the arachidonic acid cascade. Among COX isozymes, attention has been focused on inducible COX-2, which is expressed in inflammatory responses and cancer proliferation (Kujubu et al., 1991). COX-2 expression has been reported in many gastrointestinal cancers, including colorectal cancer (Eberhart et al., 1994), and research has been undertaken into the prevention of carcinogenesis by COX-2 regulation (Giardiello et al., 1993; Kawamori et al., 1998; Kune et al., 1988; Thun et al., 1991).
With regard to COX-2 expression in the gastric mucosa, not only a high rate of COX-2 expression in GC cells, but also COX-2 expression in precancerous lesions such as CAG, intestinal metaplasia, and dysplasia has been reported (Sung et al., 2000). In a study of GC tissue types, a high rate of COX-2 expression was found in intestinal-type GC (Saukkonen et al., 2001). In a study of GC according to site, cancers of the gastric cardia showed decreased COX-2 expression compared to cancers of other gastric areas (Ratnasinghe et al., 1999). In epidemiologic and animal studies, long-term use of aspirin or other NSAIDs has been reported to decrease GC risk in a dose-dependent manner (Duan et al., 2008; Hu et al., 2004; Wang et al., 2003).
In a Mongolian gerbil model of chronic active gastritis, which closely resembles HP-related chronic gastritis in humans, we evaluated the effects of etodolac, a selective COX-2 inhibitor, after initiation with a low dose of N-methyl-N-nitrosourea, a chemical carcinogen (Magari et al., 2005). The results confirmed that treatment with etodolac early in HP infection completely inhibited gastric carcinogenesis, which usually occurs at a high rate. In this model, we confirmed that proliferation of gastric mucosal epithelial tissue was significantly inhibited by etodolac, and that the development of intestinal metaplasia, thought to be a precancerous lesion, was significantly inhibited. In addition, we conducted a clinical study of GC chemoprevention using a COX-2 inhibitor in patients with metaplastic gastritis (Yanaoka et al., 2010). This study, although non-randomized, included patients who had undergone endoscopic resection of intestinal-type GC with a background of metaplastic gastritis. The incidence of metachronous cancer was evaluated in etodolac and non-treatment groups during a mean observation period of 4.2 years. The diagnosis of metaplastic gastritis was based on serum testing, as previously described. Regarding HP-related chronic gastritis stage, these patients were classified as Group D [HP(-), PG(+)]. In this study, long-term treatment with etodolac as a selective COX-2 inhibitor effectively inhibited metachronous cancer development in curatively treated, early GC patients with metaplastic gastritis. These results are in line with the results of our previous animal experiment using HP-infected Mongolian gerbils, indicating that etodolac can prevent stomach carcinogenesis involving the CAG-metaplasia-dysplasia-cancer sequence. Serious cardiovascular events, depending on the drug, have been reported with long-term administration of COX-2 inhibitors. Whether etodolac is the best choice requires further investigation. However, particularly among patients with extensive CAG, in addition to HP eradication therapy, aggressive chemoprevention using NSAIDs such as selective COX-2 inhibitors may effectively inhibit gastric carcinogenesis (Fig. 3).
3.3. Possible GC prevention by dietary habits
On the other hand, HP eradication therapy and chemoprevention using NSAIDs were not carried out in all subjects, as problems exist with adverse effects of HP eradication or chemoprevention, drug-resistant bacteria, and medical economics. Research into HP-related chronic gastritis and promoters and inhibitors of gastric carcinogenesis, and studies of alternative therapies, primarily in the form of functional foods, has thus been conducted. In the progression of HP-related chronic gastritis, besides HP virulence factors such as VacA and CagA (Hatakeyama, 2004), and host factors such as cytokine polymorphisms (El-Omar et al., 2000), environmental factors such as lifestyle and dietary habits have been shown to be involved. In particular, dietary factors have been highly implicated as the factors to which the gastric mucosa is most frequently and directly exposed. For example, high sodium intake increases gastric mucosal inflammation and the risk of gastric cancer (Nozaki et al., 2002; Shikata et al., 2006) and cigarette smoking is considered to be deeply involved in the transition of CAG to intestinal metaplasia and dysplasia (Kneller et al., 1992; Tredaniel et al., 1997), which are precancerous conditions, in a model of gastric carcinogenesis postulated by Correa (Correa and Houghton, 2007). On the other hand, epidemiologic and animal studies have found that vegetables, fruits, and green tea can inhibit gastritis and reduce gastric carcinogenesis (Kobayashi et al., 2002; Yu et al., 1995).
The Japanese apricot (JA) (
In conclusion, based on the natural history of HP-related chronic gastritis from blood test data, including the serum PG test and HP antibodies, specific prediction of the risk of GC in each individual is now possible. With this information, more effective strategies to prevent GC are becoming possible. These are anticipated to have clinical applications such as in more effective GC screening, and in establishing appropriate GC prevention.
MJ Blaser Perez-Perez G. I. Kleanthous H. Cover T. L. Peek R. M. Chyou P. H. Stemmermann G. N. Nomura A. 1995Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. , 55 10 2111 2115 0008-5472
Correa P. 1992Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. , 52 24 6735 6740 0008-5472
Correa P. Houghton J. 2007Carcinogenesis of . Gastroenterology, 133 2 659 672 0016-5085
Dinis-Ribeiro M. Yamaki G. Miki K. Costa-Pereira A. Matsukawa M. Kurihara M. 2004Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. , 11 3 141 147 0969-1413
CP Dooley Cohen H. Fitzgibbons P. L. Bauer M. MD Appleman Perez-Perez G. I. MJ Blaser 1989Prevalence of infection and histologic gastritis in asymptomatic persons. N Engl J Med, 321 23 1562 1566 0028-4793
Duan L. Wu A. H. Sullivan-Halley J. Bernstein L. 2008Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. , 17 1 126 134 1055-9965
CE Eberhart Coffey R. J. Radhika A. Giardiello F. M. Ferrenbach S. Du Bois. RN 1994Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 107 4 1183 1188 0016-5085
El -Omar E. M. Carrington M. Chow W. H. Mc Coll K. E. Bream J. H. Young H. A. Herrera J. Lissowska J. Yuan C. C. Rothman N. Lanyon G. Martin M. Fraumeni J. F. Jr Rabkin C. S. 2000Interleukin-1 polymorphisms associated with increased risk of gastric cancer. , 404 6776 398 402 0028-0836
Enomoto S. Maekita T. Ohata H. Yanaoka K. Oka M. Ichinose M. 2010aNovel risk markers for gastric cancer screening: Present status and future prospects. , 2 12 381 387 1948-5190
Enomoto S. Yanaoka K. Utsunomiya H. Niwa T. Inada K. Deguchi H. Ueda K. Mukoubayashi C. Inoue I. Maekita T. Nakazawa K. Iguchi M. Arii K. Tamai H. Yoshimura N. Fujishiro M. Oka M. Ichinose M. 2010bInhibitory effects of Japanese apricot (Prunus mume Siebold et Zucc.; Ume) on -related chronic gastritis. Eur J Clin Nutr, 64 7 714 719 1476-5640
EUROGAST Study Group. 1993An international association between infection and gastric cancer. Lancet, 341 8857 1359 1362 0140-6736
Forman D. Newell D. G. Fullerton F. Yarnell J. W. Stacey A. R. Wald N. Sitas F. 1991Association between infection with and risk of gastric cancer: evidence from a prospective investigation. BMJ, 302 6788 1302 1305 0959-8138
Fuccio L. Zagari R. M. ME Minardi Bazzoli F. 2007Systematic review: eradication for the prevention of gastric cancer. Aliment Pharmacol Ther, 25 2 133 141 0269-2813
Fujita K. Hasegawa M. Fujita M. Kobayashi I. Ozasa K. Watanabe Y. 2002Anti-Helicobacter pylori effects of Bainiku-ekisu (concentrate of Japanese apricot juice). , 99 4 379 385 0446-6586
Fukase K. Kato M. Kikuchi S. Inoue K. Uemura N. Okamoto S. Terao S. Amagai K. Hayashi S. Asaka M. 2008Effect of eradication of on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet, 372 9636 392 397 0147-4547X
Furuta T. Kaneko E. Baba S. Arai H. Futami H. 1997Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori. , 92 1 84 88 0002-9270
Giardiello F. M. Hamilton S. R. Krush A. J. Piantadosi S. Hylind L. M. Celano P. Booker S. V. Robinson C. R. Offerhaus G. J. 1993Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 328 18 1313 1316 0028-4793
Gotoda T. 2007Endoscopic resection of early gastric cancer. , 10 1 1 11 1436-3291
Guarner J. Herrera-Goepfert R. Mohar A. Sanchez L. Halperin D. Ley C. Parsonnet J. 1999Interobserver variability in application of the revised Sydney classification for gastritis. , 30 12 1431 1434 0046-8177
Hatakeyama M. 2004Oncogenic mechanisms of the CagA protein. Nat Rev Cancer, 4 9 688 694 0147-4175X
Hattori Y. Tashiro H. Kawamoto T. Kodama Y. 1995Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens. , 86 12 1210 1215 0910-5050
Hirayama F. Takagi S. Iwao E. Yokoyama Y. Haga K. Hanada S. 1999Development of poorly differentiated adenocarcinoma and carcinoid due to long-term colonization in Mongolian gerbils. J Gastroenterol, 34 4 450 454 0944-1174
Hirschowitz B. I. 1957Pepsinogen: its origins, secretion and excretion. , 37 4 475 511 0031-9333
Honda S. Fujioka T. Tokieda M. Satoh R. Nishizono A. Nasu M. 1998Development of -induced gastric carcinoma in Mongolian gerbils. Cancer Res, 58 19 4255 4259 0008-5472
Hu P. J. Yu J. Zeng Z. R. Leung W. K. Lin H. L. BD Tang Bai A. H. Sung J. J. 2004Chemoprevention of gastric cancer by celecoxib in rats. , 53 2 195 200 0017-5749
Huang J. Q. Sridhar S. Chen Y. Hunt R. H. 1998Meta-analysis of the relationship between seropositivity and gastric cancer. Gastroenterology, 114 6 1169 1179 0016-5085
Ichinose M. Yahagi N. Oka M. Ikeda H. Miki K. Omata M. 2001Screening for gastric cancer in Japan, In: , Wu GY, Aziz K, editors, 255Humana Press, 0-89603-865-3New Jersey
International Agency for Research on Cancer (IARC). 1994Schistosomes,liver flukes, and Working group on the evaluation of carcinogenic risks to humans. IARC Monogr Eval Carcinog Risks Hum, 61June 1994), 177 241
Jones R. 2010Japanese apricots reported to inhibit inflammation and gastritis progression related to infection. Nat Rev Gastroenterol Hepatol, 7 9 478
Kageyama T. Ichinose M. 2003Diversity of structure and function of pepsinogens and pepsins , 3 159 178
Kakushima N. Fujishiro M. 2008Endoscopic submucosal dissection for gastrointestinal neoplasms. , 14 19 2962 2967 1007-9327
Kawamori T. Rao C. V. Seibert K. BS Reddy 1998Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. , 58 3 409 412 0008-5472
Kimura K. 1972Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. , 63 4 584 592 0016-5085
Kitahara F. Kobayashi K. Sato T. Kojima Y. Araki T. MA Fujino 1999Accuracy of screening for gastric cancer using serum pepsinogen concentrations. , 44 5 693 697 0017-5749
Kneller R. W. You W. C. Chang Y. S. Liu W. D. Zhang L. Zhao L. Xu G. W. Fraumeni J. F. Jr Blot W. J. 1992Cigarette smoking and other risk factors for progression of precancerous stomach lesions. , 84 16 1261 1266 0027-8874
Kobayashi M. Tsubono Y. Sasazuki S. Sasaki S. Tsugane S. 2002Vegetables, fruit and risk of gastric cancer in Japan: a 10-year follow-up of the JPHC Study Cohort I. , 102 1 39 44 0020-7136
Kodoi A. Yoshihara M. Sumii K. Haruma K. Kajiyama G. 1995Serum pepsinogen in screening for gastric cancer. , 30 4 452 460 0944-1174
Kujubu D. A. BS Fletcher Varnum B. C. Lim R. W. Herschman H. R. 1991TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 266 20 12866 12872 0021-9258
Kune G. A. Kune S. Watson L. F. 1988Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. , 48 15 4399 4404 0008-5472
Magari H. Shimizu Y. Inada K. Enomoto S. Tomeki T. Yanaoka K. Tamai H. Arii K. Nakata H. Oka M. Utsunomiya H. Tsutsumi Y. Tsukamoto T. Tatematsu M. Ichinose M. 2005Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in -infected Mongolian gerbils. Biochem Biophys Res Commun, 334 2 606 612 0000-6291X
Marshall B. J. Warren J. R. 1984Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. , 1 8390 1311 1315 0140-6736
Meister H. Holubarsch C. Haferkamp O. Schlag P. Herfarth C. 1979Gastritis, intestinal metaplasia and dysplasia versus benign ulcer in stomach and duodenum and gastric carcinoma-- a histotopographical study. , 164 3 259 269 0344-0338
Miki K. Ichinose M. Shimizu A. Huang S. C. Oka H. Furihata C. Matsushima T. Takahashi K. 1987Serum pepsinogens as a screening test of extensive chronic gastritis. , 22 2 133 141 0435-1339
Miki K. Ichinose M. Ishikawa K. B. Yahagi N. Matsushima M. Kakei N. Tsukada S. Kido M. Ishihama S. Shimizu Y. Suzuki T. Kurokawa K. 1993Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. , 84 10 1086 1090 0910-5050
Miki K. Morita M. Sasajima M. Hoshina R. Kanda E. Urita Y. 2003Usefulness of gastric cancer screening using the serum pepsinogen test method. , 98 4 735 739 0002-9270
Mukoubayashi C. Yanaoka K. Ohata H. Arii K. Tamai H. Oka M. Ichinose M. 2007Serum pepsinogen and gastric cancer screening. , 46 6 261 266 1349-7235
Nakajima T. Oda I. Gotoda T. Hamanaka H. Eguchi T. Yokoi C. Saito D. 2006Metachronous gastric cancers after endoscopic resection: how effective is annual endoscopic surveillance? , 9 2 93 98 1436-3291
Nomura A. Stemmermann G. N. Chyou P. H. Kato I. Perez-Perez G. I. MJ Blaser 1991infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med, 325 16 1132 1136 0028-4793
Nozaki K. Shimizu N. Inada K. Tsukamoto T. Inoue M. Kumagai T. Sugiyama A. Mizoshita T. Kaminishi M. Tatematsu M. 2002Synergistic promoting effects of infection and high-salt diet on gastric carcinogenesis in Mongolian gerbils. Jpn J Cancer Res, 93 10 1083 1089 0910-5050
Ohata H. Kitauchi S. Yoshimura N. Mugitani K. Iwane M. Nakamura H. Yoshikawa A. Yanaoka K. Arii K. Tamai H. Shimizu Y. Takeshita T. Mohara O. Ichinose M. 2004Progression of chronic atrophic gastritis associated with infection increases risk of gastric cancer. Int J Cancer, 109 1 138 143 0020-7136
Ohata H. Oka M. Yanaoka K. Shimizu Y. Mukoubayashi C. Mugitani K. Iwane M. Nakamura H. Tamai H. Arii K. Nakata H. Yoshimura N. Takeshita T. Miki K. Mohara O. Ichinose M. 2005Gastric cancer screening of a high-risk population in Japan using serum pepsinogen and barium digital radiography. , 96 10 713 720 1347-9032
Otsuka T. Tsukamoto T. Tanaka H. Inada K. Utsunomiya H. Mizoshita T. Kumagai T. Katsuyama T. Miki K. Tatematsu M. 2005Supressive effect of fruits-juice concentrate of Sieb. et Zucc. (Japanese apricot, Ume) on Helicobacter pylori-induced glandular stoach lesion in Mongolian gerbils Asian Pacific J Cancer Prev, 6Jul-05), 337 341
Parsonnet J. Friedman G. D. Vandersteen D. P. Chang Y. Vogelman J. H. Orentreich N. Sibley R. K. 1991infection and the risk of gastric carcinoma. N Engl J Med, 325 16Oct 17 1991), 1127 1131 0028-4793
Plummer M. Buiatti E. Lopez G. Peraza S. Vivas J. Oliver W. Munoz N. 1997Histological diagnosis of precancerous lesions of the stomach: a reliability study. , 26 4 716 720 0300-5771
Ratnasinghe D. Tangrea J. A. MJ Roth Dawsey S. M. Anver M. BA Kasprzak Hu N. Wang Q. H. Taylor P. R. 1999Expression of cyclooxygenase-2 in human adenocarcinomas of the gastric cardia and corpus. , 6 5Sep-99), 965 968 0102-1335X
Samloff I. M. Varis K. Ihamaki T. Siurala M. Rotter J. I. 1982Relationships among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives of patients with pernicious anemia. , 83 1Pt 2, (82), 204 209 0016-5085
Saukkonen K. Nieminen O. van Rees B. Vilkki S. Harkonen M. Juhola M. Mecklin J. P. Sipponen P. Ristimaki A. 2001Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. , 7 7 1923 1931 1078-0432
Shikata K. Kiyohara Y. Kubo M. Yonemoto K. Ninomiya T. Shirota T. Tanizaki Y. Doi Y. Tanaka K. Oishi Y. Matsumoto T. Iida M. 2006A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. , 119 1 196 201 0020-7136
Shimizu N. Inada K. Nakanishi H. Tsukamoto T. Ikehara Y. Kaminishi M. Kuramoto S. Sugiyama A. Katsuyama T. Tatematsu M. 1999infection enhances glandular stomach carcinogenesis in Mongolian gerbils treated with chemical carcinogens. Carcinogenesis, 20 4 669 676 0143-3334
Sipponen P. Kekki M. Haapakoski J. Ihamaki T. Siurala M. 1985Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. , 35 2Feb 15 1985), 173 177 0020-7136
Sipponen P. Kosunen T. U. Valle J. Riihela M. Seppala K. 1992infection and chronic gastritis in gastric cancer. J Clin Pathol, 45 4 319 323 0021-9746
Siurala M. Varis K. Wiljasalo M. 1966Studies of patients with atrophic gastritis: a 10-15-year follow-up. , 1 1 40 48 0036-5521
Sugiyama A. Maruta F. Ikeno T. Ishida K. Kawasaki S. Katsuyama T. Shimizu N. Tatematsu, M. 1998infection enhances N-methyl-N-nitrosourea-induced stomach carcinogenesis in the Mongolian gerbil. Cancer Res, 58 10 2067 2069 0008-5472
Sung J. J. Leung W. K. Go M. Y. To K. F. AS Cheng Ng E. K. Chan F. K. 2000Cyclooxygenase-2 expression in -associated premalignant and malignant gastric lesions. Am J Pathol, 157 3 729 735 0002-9440
Take S. Mizuno M. Ishiki K. Nagahara Y. Yoshida T. Yokota K. Oguma K. 2007Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after eradication therapy in patients with peptic ulcer diseases. J Gastroenterol, 42Suppl 17, (07), 21 27 0944-1174
Talley N. J. Zinsmeister A. R. Weaver A. Di Magno E. P. Carpenter H. A. Perez-Perez G. I. MJ Blaser 1991Gastric adenocarcinoma and infection. J Natl Cancer Inst, 83 23 1734 1739 0027-8874
Tatematsu M. Tsukamoto T. Toyoda T. 2007Effects of eradication of on gastric carcinogenesis in experimental models. J Gastroenterol, 42Suppl 17, (07), 7 9 0944-1174
Tatsuta M. Saegusa T. Okuda S. 1973Studies on Gastritis in the Upper Portion of Stomach by Endoscopic Congo Red Test , 5 61 69
Tatsuta M. Iishi H. Nakaizumi A. Okuda S. Taniguchi H. Hiyama T. Tsukuma H. Oshima A. 1993Fundal atrophic gastritis as a risk factor for gastric cancer. , 53 1 70 74 0020-7136
Testoni P. A. Masci E. Marchi R. Guslandi M. Ronchi G. Tittobello A. 1987Gastric cancer in chronic atrophic gastritis. Associated gastric ulcer adds no further risk. , 9 3 298 302 0192-0790
MJ Thun MM Namboodiri Heath C. W. Jr 1991Aspirin use and reduced risk of fatal colon cancer. , 325 23 1593 1596 0028-4793
Tokieda M. Honda S. Fujioka T. Nasu M. 1999Effect of infection on the N-methyl-N’-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in mongolian gerbils. Carcinogenesis, 20 7 1261 1266 0143-3334
Tredaniel J. Boffetta P. Buiatti E. Saracci R. Hirsch A. 1997Tobacco smoking and gastric cancer: review and meta-analysis. , 72 4 565 573 0020-7136
Uemura N. Okamoto S. Yamamoto S. Matsumura N. Yamaguchi S. Yamakido M. Taniyama K. Sasaki N. Schlemper R. J. 2001infection and the development of gastric cancer. N Engl J Med, 345 11 784 789 0028-4793
Wang W. H. Huang J. Q. Zheng G. F. Lam S. K. Karlberg J. Wong B. C. 2003Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. , 95 23 1784 1791 1460-2105
Watabe H. Mitsushima T. Yamaji Y. Okamoto M. Wada R. Kokubo T. Doi H. Yoshida H. Kawabe T. Omata M. 2005Predicting the development of gastric cancer from combining antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut, 54 6 764 768 0017-5749
Watanabe T. Tada M. Nagai H. Sasaki S. Nakao M. 1998infection induces gastric cancer in mongolian gerbils. Gastroenterology, 115 3 642 648 0016-5085
Watanabe Y. Kurata J. H. Mizuno S. Mukai M. Inokuchi H. Miki K. Ozasa K. Kawai K. 1997infection and gastric cancer. A nested case-control study in a rural area of Japan. Dig Dis Sci, 42 7 1383 1387 0163-2116
Wong B. C. Lam S. K. Wong W. M. Chen J. S. Zheng T. T. Feng R. E. Lai K. C. Hu W. H. Yuen S. T. Leung S. Y. Fong D. Y. Ho J. Ching C. K. 2004eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA, 291 2 187 194 1538-3598
Yanaoka K. Oka M. Mukoubayashi C. Yoshimura N. Enomoto S. Iguchi M. Magari H. Utsunomiya H. Tamai H. Arii K. Ohata H. Fujishiro M. Takeshita T. Mohara O. Ichinose M. 2008aCancer high-risk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. , 17 4 838 845 1055-9965
Yanaoka K. Oka M. Yoshimura N. Mukoubayashi C. Enomoto S. Iguchi M. Magari H. Utsunomiya H. Tamai H. Arii K. Yamamichi N. Fujishiro M. Takeshita T. Mohara O. Ichinose M. 2008bRisk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and antibody levels. Int J Cancer, 123 4 917 926 1097-0215
Yanaoka K. Oka M. Ohata H. Yoshimura N. Deguchi H. Mukoubayashi C. Enomoto S. Inoue I. Iguchi M. Maekita T. Ueda K. Utsunomiya H. Tamai H. Fujishiro M. Iwane M. Takeshita T. Mohara O. Ichinose M. 2009Eradication of prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int J Cancer, 125 11 2697 2703 1097-0215
Yanaoka K. Oka M. Yoshimura N. Deguchi H. Mukoubayashi C. Enomoto S. Maekita T. Inoue I. Ueda K. Utsunomiya H. Iguchi M. Tamai H. Fujishiro M. Nakamura Y. Tsukamoto T. Inada K. Takeshita T. Ichinose M. 2010Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a -negative precancerous lesion. Int J Cancer, 126 6Mar 2010), 1467 1473 1097-0215
Yoshihara M. Sumii K. Haruma K. Kiyohira K. Hattori N. Tanaka S. Kajiyama G. Shigenobu T. 1997The usefulness of gastric mass screening using serum pepsinogen levels compared with photofluorography. , 46 2 81 86 0018-2052
You W. C. Brown L. M. Zhang L. Li J. Y. Jin M. L. Chang Y. S. Ma J. L. Pan K. F. Liu W. D. Hu Y. Crystal-Mansour S. Pee D. Blot W. J. Fraumeni J. F. Jr. Xu G. W. Gail M. H. 2006Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. , 98 14 974 983 1460-2105
Yu G. P. Hsieh C. C. Wang L. Y. Yu S. Z. Li X. L. Jin T. H. 1995Green-tea consumption and risk of stomach cancer: a population-based case-control study in Shanghai, China. , 6 6 532 538 0957-5243
Zheng Q. Chen X. Y. Shi Y. Xiao S. D. 2004Development of gastric adenocarcinoma in Mongolian gerbils after long-term infection with Helicobacter pylori. , 19 10 1192 1198 0815-9319